|Practical Strategies for Improving Outcomes in MDS: New HMAs, Combination and Novel Treatments|
Aziz Nazha, MD
|Release Date: February 26, 2020|
Expiration Date: February 26, 2021
Risk stratification is critical when managing patients with MDS because guideline consensus treatment algorithms are distinguished by lower-risk disease and higher-risk disease. In this activity, Dr. Aziz Nazha explains next steps after risk stratifying your patient and the goal of therapy based on this assessment. He will also review novel formulations of hypomethylating agents (HMAs) in development and their potential use in MDS. Lastly, Dr. Nazha will cover key genetic mutations and the potential future investigations.Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Astex Pharmaceuticals, Celgene Corporation, and Takeda Oncology
|Begin, Earn CreditView Only, No Credit|